Avidity Biosciences Gains Momentum: RNA Soars as Novartis Acquires for $12 Billion

Avidity Biosciences’ (NASDAQ:RNA) stock experienced a significant surge in premarket trading on Monday, October 27, 2025, following an announcement of a landmark acquisition deal with pharmaceutical giant Novartis AG. The all-stock transaction is valued at $12 billion and will see Novartis acquire Avidity’s late-stage clinical programs targeting rare genetic neuromuscular diseases. The deal offers substantial value to Avidity shareholders, who will receive a generous premium of up to 62% over the recent share price.